Table I.

Level of evidence and strength of comorbidity screening recommendations in HS

Comorbidity in HS	Level of evidence	Strength of recommendation	Is screening recommended?*
Acne vulgaris/conglobata	II	B	Yes
Dissecting cellulitis of scalp	II	B	Yes
Pilonidal cyst	II	B	Yes
Pyoderma gangrenosum	II	B	Yes, for patients with ulcerations, regardless of inflammatory bowel disease status
Depression	II	B	Yes
Anxiety	II	B	Yes
Suicidality	II	B	Yes, for patients who have known psychiatric disease, including substance use, or those who exhibit signs of psychological distress
Tobacco	II	B	Yes
Substance misuse	II	B	Yes, for patients with chronic pain, depression, or anxiety
Polycystic ovary syndrome	II	B	Yes
Obesity	II	B	Yes
Dyslipidemia	II	B	Yes
Diabetes mellitus	II	B	Yes
Metabolic syndrome	II	B	Yes
Hypertension	II	B	Yes
Cardiovascular disease	II	B	Yes
Inflammatory bowel disease	II	B	Yes
Spondyloarthritis	II	B	Yes
Sexual dysfunction	II	B	Yes
Down syndrome	II	B	Yes, screen patients with trisomy 21 for HS
Thyroid disease	–	–	Insufficient evidence
Nonalcoholic fatty liver disease	–	–	Insufficient evidence
Obstructive sleep apnea	–	–	Insufficient evidence
Renal disease	–	–	Insufficient evidence
Sleep disturbances	–	–	Insufficient evidence
Alzheimer disease	II	B	No
Herpes zoster	II	B	No
Lymphomas	II	B	No
Psoriasis vulgaris	II	B	No

HS, Hidradenitis suppurativa.

^*A recommendation for or against screening is based on the (1) findings and overall level of evidence from the systematic review, including the absolute prevalence of the condition and magnitude of association with HS; (2) potential benefits, harms, costs, and feasibility of screening; and (3) latest population-based screening recommendations in the general population, if available.